HUE030789T2 - Fejlesztett depó formuláció - Google Patents

Fejlesztett depó formuláció Download PDF

Info

Publication number
HUE030789T2
HUE030789T2 HUE08767765A HUE08767765A HUE030789T2 HU E030789 T2 HUE030789 T2 HU E030789T2 HU E08767765 A HUE08767765 A HU E08767765A HU E08767765 A HUE08767765 A HU E08767765A HU E030789 T2 HUE030789 T2 HU E030789T2
Authority
HU
Hungary
Prior art keywords
formulation
aktiv
áris
weight
polymer
Prior art date
Application number
HUE08767765A
Other languages
English (en)
Inventor
Jeremy C Wright
Felix Theeuwes
John W Gibson
Keith E Branham
Stefania Sjobeck
Original Assignee
Durect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Durect Corp filed Critical Durect Corp
Publication of HUE030789T2 publication Critical patent/HUE030789T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biological Depolymerization Polymers (AREA)

Claims (6)

  1. »ä I NH-100024232 (íj szacharóz-seetát1zobt.#átot (SAIS); Ί$:Ί 'ÍÉi&amp;iárMliSP tömegéhez képest 15-45% Sömegszázaiékban lineáris poíí(ÍaKtld'k<3'öhko]íd)-ot amelynek Magos molekulatömege Kisebb vagy egyenlő. mini: 15 OOÖ Dalion, ás amely íaktld ismétlődő egységekkel rendelkezik az összes: ismétlődő egységhez Képest R arányban, ebei R megfelel az alábbiaknak: 0,65 £ R sr 0,35; és (Ili) N-metil-pirrolidont, ahol az N-metii-pirroiidcn a formyláció teljes tömegéhez képest 20% tömegszázalékná! nagyobb tnennyiségban van jeien, és 0,55 s R < 0,86, valamint ahol az N-mehl-pírrolidon a fertnuláoló teljes tömegéhez képest 10% tömegszázaiéknéí nagyobb vagy egyenlő mennyiségben van jeien, és 0,86 c R < 0,95.
  2. 2. Fofmulsclő az 1-es igénypont szedni, éhé! f pptleköd-kő'giikotíd) a tbfniüiéeiő teijes; tömégéhéz képest 15-35%: tomegazézalèk mennyiségben van jelen,
  3. 8. Formuiáció az 1-es vagy 2-es igénypont szerint, aboi R ériéke 0,56-töl 0,86-ig térted.
    4. Forrmtloib az 1-es vagy 2-es igénypont szerint, aboi R értéke nagyobb, mint 0,65 á##$§4§ lerjéÉ :5, formulácié az eddigi igénypontok bármelyike szednt ahoi az N-meül-pirrolidan a forrnalééi: teljes tömegéhez képes? 26%: térnegszàzalèk vagy arma! nagyobb mennyiségben van jelen. 6. iomnuiäelö a: &amp;ás Igénypont szerint, ebei az ht-patii-pirroiidöp e femtüieplo ·ν^χ· annál nagyobb mennyiségben van jelen.
    7. Gyógyszerészeti összetétel, amely tartalmazza a ^ámpá^k®'lltáí:'í^^ÍíoiSöl^ii,: vaiamihf tartalmaz egy biológiailag aktív hatóanyagot.
    8. Összetétel a 7-es igédypbnt szerint, abbl a bioüglaííég aktiv hatóanyag tMsimaz átípúsós antipszicmebkumot. t. összététeí a ÉeS: Igépypsnt szőriét, ahol az adpasos antipskiehetikyrn tertaimaz riapefidont vagy andak gyogyszefés^Siag; elfogadható sóját vagy pirnörfját,.
  4. 10, Összéíéteí a 7-9 igénypontok bármelyike szerintiabol : a öioiögisiíag aKíív hatóanyag a fermeléció téijss:tpfnegèftez Képest: 1 -20% tÖSTisgazázatek mennyiségijén van jelen,
  5. 11, Gsszetéteiia íMÖ igénypontok {toely^Âerip|.''âh#iIi^j^8llô§ akiiv hatóanyag é förmaiéciö teljes tömegéhez képest 2-20% tömegszázaiék mennyiségben; yen jelen.
  6. 12, Összetétel a M1 igénypontok bármelyike; szabii ahö!;;a;||öl||iaiiäg aktiv hatögnyli;:te^ÄÄ4^N' teÉéph&amp;f képest 2-106« tómegszázaiék mennyiségben van jelen.
HUE08767765A 2007-05-18 2008-05-16 Fejlesztett depó formuláció HUE030789T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93073907P 2007-05-18 2007-05-18

Publications (1)

Publication Number Publication Date
HUE030789T2 true HUE030789T2 (hu) 2017-06-28

Family

ID=39708928

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE08767765A HUE030789T2 (hu) 2007-05-18 2008-05-16 Fejlesztett depó formuláció

Country Status (12)

Country Link
US (8) US20080287464A1 (hu)
EP (2) EP3115038A1 (hu)
JP (4) JP5599705B2 (hu)
CN (2) CN101677952B (hu)
AU (1) AU2008254538B2 (hu)
CA (1) CA2686137C (hu)
DK (1) DK2167039T3 (hu)
ES (1) ES2606951T3 (hu)
HU (1) HUE030789T2 (hu)
IL (1) IL202181A (hu)
PL (1) PL2167039T3 (hu)
WO (1) WO2008143992A2 (hu)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US20090068243A1 (en) * 2007-04-03 2009-03-12 Brian Bray Novel formulations for delivery of antiviral peptide therapeutics
HUE030789T2 (hu) 2007-05-18 2017-06-28 Durect Corp Fejlesztett depó formuláció
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
US8524267B2 (en) 2008-04-18 2013-09-03 Warsaw Orthopedic, Inc. Dexamethasone formulations in a biodegradable material
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
DK2394664T3 (en) * 2010-05-31 2016-09-12 Laboratorios Farmacéuticos Rovi S A Antipsychotic injectable depot composition
PT2394663T (pt) 2010-05-31 2021-11-26 Farm Rovi Lab Sa Composições para implantes biodegradáveis injectáveis
EP2643009A4 (en) * 2010-11-24 2015-04-01 Durect Corp BIODEGRADABLE DRUG DELIVERY COMPOSITION
DK2529756T3 (da) * 2011-05-31 2021-08-02 Farm Rovi Lab Sa Risperidon- og/eller paliperidon-implantatformulering
EP2782590A4 (en) * 2011-11-23 2016-08-03 Durect Corp BIODEGRADABLE AND MEDIUM-RADIATED STERILIZED MEDICAMENTAL COMPOSITIONS
US20140308352A1 (en) * 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
BR112015022023B1 (pt) * 2013-03-11 2022-12-06 Durect Corporation Composição de liberação controlada injetável compreendendo transportador líquido de alta viscosidade
EP3079668A1 (en) 2013-12-09 2016-10-19 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
AR105947A1 (es) 2015-03-18 2017-11-29 Santen Pharmaceutical Co Ltd Composición farmacéutica oftálmica de liberación prolongada y método para estabilizar una droga contenida en una preparación de depósito oftálmica
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
MX2018016424A (es) 2016-06-30 2019-08-12 Durect Corp Formulaciones de deposito.
US20220265830A1 (en) * 2019-07-18 2022-08-25 Durect Corporation Long-acting formulations and vehicles
US20220257619A1 (en) * 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법
TW202313047A (zh) 2021-09-21 2023-04-01 西班牙商禾霏藥品實驗室有限公司 抗精神病可注射儲積型組合物

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4725442A (en) 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4622219A (en) 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
US4891225A (en) * 1984-05-21 1990-01-02 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
IT1198449B (it) * 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5149543A (en) 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
NZ260909A (en) * 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
US5643605A (en) * 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
CA2176716C (en) 1993-11-19 2009-04-07 Ramstack, J. Michael Preparation of biodegradable microparticles containing a biologically active agent
US5968542A (en) * 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US6413536B1 (en) * 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
DE69737515T2 (de) 1996-05-07 2007-12-06 Alkermes, Inc., Cambridge Micropartikel
ATE318580T1 (de) * 1996-12-20 2006-03-15 Alza Corp Gelzusammensetzungen und verfahren
ES2359973T3 (es) * 1998-03-19 2011-05-30 MERCK SHARP &amp; DOHME CORP. Composiciones poliméricas líquidas para la liberación controlada de sustancias bioactivas.
US7208011B2 (en) * 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6291013B1 (en) * 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
AU2001245346A1 (en) 2000-06-28 2002-01-08 Atul J. Shukla Biodegradable vehicles and delivery systems of biologically active substances
WO2002067895A2 (en) * 2000-11-16 2002-09-06 Durect Corporation Implant dosage form and use thereof for the delivery of a cholesterol lowering agent
US20040018238A1 (en) * 2001-02-26 2004-01-29 Shukla Atul J Biodegradable vehicles and delivery systems of biolgically active substances
WO2002076344A1 (en) * 2001-03-23 2002-10-03 Durect Corporation Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space
GB0112324D0 (en) * 2001-05-21 2001-07-11 Croda Int Plc Compounds
DE60239556D1 (de) 2001-11-14 2011-05-05 Durect Corp Katheterinjizierbare depotzusammensetzungen und deren verwendung
US20030170289A1 (en) 2001-11-14 2003-09-11 Guohua Chen Injectable depot compositions and uses thereof
KR20040065153A (ko) 2001-11-14 2004-07-21 알자 코포레이션 주입가능한 데포 조성물
US20040258731A1 (en) 2001-11-21 2004-12-23 Tsuyoshi Shimoboji Preparation approriate for cartilage tissue formation
TWI314464B (en) 2002-06-24 2009-09-11 Alza Corp Reusable, spring driven autoinjector
AR039729A1 (es) 2002-06-25 2005-03-09 Alza Corp Formulaciones de deposito de corta duracion
US20040109893A1 (en) * 2002-06-25 2004-06-10 Guohua Chen Sustained release dosage forms of anesthetics for pain management
MXPA05001244A (es) 2002-07-31 2005-06-08 Alza Corp Composiciones de deposito de polimero multimodal inyectable y usos de las mismas.
US7097634B2 (en) 2002-07-31 2006-08-29 Alza Corporation Injection device providing automatic needle retraction
RU2355385C2 (ru) 2002-11-06 2009-05-20 Алза Корпорейшн Композиции пролонгированного действия с контролируемым высвобождением
AU2003299659A1 (en) 2002-12-13 2004-07-09 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
DE10312346A1 (de) * 2003-03-20 2004-09-30 Bayer Healthcare Ag Kontrolliertes Freisetzungssystem
WO2005021046A1 (en) 2003-09-01 2005-03-10 Fh Faulding & Co Ltd Compositions and methods for delivery of biologically active agents
US20050281879A1 (en) 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
US20100016267A1 (en) * 2004-03-15 2010-01-21 Felix Theeuwes Pharmaceutical compositions for administraton to a sinus
US20050240166A1 (en) * 2004-04-26 2005-10-27 Microsolutions, Inc. Implantable device, formulation and method for anti-psychotic therapy using risperidone
US8852638B2 (en) * 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
CN101400363B (zh) 2006-01-18 2012-08-29 昌达生物科技公司 具有增强的稳定性的药物组合物
HUE030789T2 (hu) * 2007-05-18 2017-06-28 Durect Corp Fejlesztett depó formuláció
CN102131483A (zh) 2008-02-08 2011-07-20 昌达生物科技公司 可控给药非聚合组合物
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material

Also Published As

Publication number Publication date
US20230146925A1 (en) 2023-05-11
IL202181A (en) 2014-11-30
EP2167039B1 (en) 2016-09-28
US20160279131A1 (en) 2016-09-29
US20190030032A1 (en) 2019-01-31
AU2008254538A1 (en) 2008-11-27
EP3115038A1 (en) 2017-01-11
CN101677952B (zh) 2012-12-05
US10028957B2 (en) 2018-07-24
US20080287464A1 (en) 2008-11-20
JP2014193880A (ja) 2014-10-09
CN101677952A (zh) 2010-03-24
CN103007288A (zh) 2013-04-03
CA2686137A1 (en) 2008-11-27
PL2167039T3 (pl) 2017-03-31
CA2686137C (en) 2021-01-12
US20130289053A1 (en) 2013-10-31
JP2018158921A (ja) 2018-10-11
WO2008143992A3 (en) 2009-09-24
AU2008254538B2 (en) 2013-11-07
CN103007288B (zh) 2015-02-11
JP5599705B2 (ja) 2014-10-01
US20200101073A1 (en) 2020-04-02
JP6339640B2 (ja) 2018-06-06
IL202181A0 (en) 2010-06-16
WO2008143992A2 (en) 2008-11-27
JP6018603B2 (ja) 2016-11-02
ES2606951T3 (es) 2017-03-28
DK2167039T3 (en) 2017-01-09
US20160045601A1 (en) 2016-02-18
US20210121467A1 (en) 2021-04-29
EP2167039A2 (en) 2010-03-31
JP2017014241A (ja) 2017-01-19
JP2010527926A (ja) 2010-08-19

Similar Documents

Publication Publication Date Title
DK2167039T3 (en) Improved depot formulations
JP4276807B2 (ja) 高粘度液体により制御された送達システム及び内科又は外科用デバイス
DE69634277T2 (de) Kontrolliertes zuführsystem mit einer flüssigkeit von hoher viskosität
US5747058A (en) High viscosity liquid controlled delivery system
US20040101557A1 (en) High viscosity liquid controlled delivery system and medical or surgical device
JP2016512523A (ja) 高粘性液体キャリアを含む注射用制御放出組成物
AU2013202476B2 (en) Improved depot formulations
MXPA97009606A (en) Liquid system of controlled release and viscosity elev